Astec LifeSciences Limited (ASTEC) Q2 FY27 Financial Results: PAT ₹-18.7 & Revenue ₹84.3

Investor Takeaways

• Revenue declined 8% YoY to ₹84.3 crore in Q1FY27
• EBITDA improved from -₹10.5 crore to ₹0.1 crore YoY
• Net loss narrowed to ₹-18.7 crore from ₹-33.0 crore YoY
• ⚠️ No specific risks identified in this filing

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

What Changed

The filing reports consolidated revenue of ₹84.3 crore for Q1FY27, representing an 8% year-on-year decline from ₹91.6 crore. Despite the revenue contraction, EBITDA turned positive at ₹0.1 crore compared to a ₹10.5 crore loss in the same quarter last year. The net loss also narrowed significantly to ₹-18.7 crore from ₹-33.0 crore YoY. These improvements indicate progress in cost management and operational efficiency, even amid lower sales volume. The company achieved EBITDA breakeven, signaling potential stabilization in core operations. Quarterly trends show sequential improvement in profitability metrics, with Q1FY27 EBITDA positive for the first time in recent quarters.

Peer Comparison

Astec LifeSciences trades at a negative P/E ratio, reflecting its current un profitability, while peers exhibit positive valuations. The company's market capitalization is significantly lower than the largest peer, indicating a smaller market presence.

Risks & Concerns

No specific risks identified in this filing.

Quarterly Trend